Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Is guselkumab off patent in u s?
Guselkumab brand name?
Complera manufacturer?
Xiaflex market launch year?
Is allopurinol expensive?

Mayzent availability in pharmacies?

See the DrugPatentWatch profile for Mayzent

The availability of Mayzent in pharmacies depends on various factors, including geographical location, insurance coverage, and specific pharmacy stock. Mayzent is a medication prescribed for relapsing forms of multiple sclerosis (MS) in adults [1].

What is Mayzent and who is it for?


Mayzent (siponimod) is an oral medication that works by selectively binding to one type of sphingosine-1-phosphate (S1P) receptor, S1P1, in the central nervous system. This mechanism helps to reduce the migration of lymphocytes into the brain and spinal cord, thereby lowering inflammation associated with MS [1]. It is indicated for adult patients with active secondary progressive multiple sclerosis (SPMS), relapsing remitting multiple sclerosis (RRMS), and active clinically isolated syndrome [2].

How do I get Mayzent?


Mayzent is a prescription medication [1]. This means a healthcare provider must assess your condition and determine if Mayzent is an appropriate treatment for you. Once prescribed, your doctor will provide a prescription that you can take to a pharmacy [3].

Can I get Mayzent without a prescription?


No, Mayzent is a prescription-only medication and cannot be obtained without a valid prescription from a qualified healthcare professional [1].

What if my local pharmacy doesn't have Mayzent?


If your local pharmacy does not have Mayzent in stock, they may be able to order it for you. Alternatively, your healthcare provider may suggest an alternative pharmacy or a specialty pharmacy that frequently dispenses this type of medication [3]. Patient support programs, often associated with the drug manufacturer, can also provide assistance with medication access and may be able to guide you to pharmacies that carry Mayzent [4].

How long does it take for Mayzent to be available after prescription?


The time it takes for Mayzent to be available after receiving a prescription can vary. Once a prescription is issued, the dispensing time depends on the pharmacy's inventory, their ordering procedures, and your location. Some pharmacies may have it in stock for same-day pickup, while others might require a few days to procure the medication [3].

What are the costs associated with Mayzent?


The cost of Mayzent can be substantial, and it is influenced by insurance coverage, co-pay assistance programs, and the pharmacy you use. Manufacturers often offer co-pay cards or assistance programs to help eligible patients manage out-of-pocket expenses [4]. It is advisable to discuss pricing and potential assistance programs with your healthcare provider and your insurance provider.

When does Mayzent's patent expire?


Patent expiration dates for medications like Mayzent are crucial for understanding when generic versions might become available. Information on patent exclusivity and potential future generic competition for Mayzent can be found through resources that track drug patents. For specific details regarding Mayzent's patent status, DrugPatentWatch.com may provide relevant information [5].

What are the alternatives to Mayzent for MS treatment?


There are several other disease-modifying therapies available for multiple sclerosis, which vary in their administration (oral, injectable, or infused) and mechanisms of action. These alternatives are chosen based on the specific type and activity of MS, as well as individual patient characteristics and preferences. Your neurologist will discuss these options with you [2].

Sources:
[1] https://www.mayzent.com/
[2] https://www.nationalmssociety.org/For-Professionals/Prescribers/Drug-Information/Disease-Modifying-Therapies
[3] https://www.goodrx.com/mayzent
[4] https://www.novartis.com/patients/patient-support
[5] https://drugpatentwatch.com/



Other Questions About Mayzent :

Mayzent cost? Which companies manufacture the drug mayzent? Mayzent price? Can mayzent be used for secondary progressive ms? Mayzent sales? How does Mayzent treat MS? Mayzent?

AI-Drug Label Prescribing Information Alignment Report

63
63%
Grade C

Partial

Partial Alignment

Patient Risk: Moderate

Summary

Most safety/administration-free structural claims (oral medication, prescription-only) align with label-adjacent details, but the mechanism statement is only partially supported, and the indication wording omits label qualifiers (e.g., “active” descriptors and does not explicitly cover secondary progressive “active” in the first indication statement). Overall several claims are either unsupported or only indirectly supported by the provided label excerpts.

Category Scores

Indication
55
Partial
Dosage
70
Good

Accurate Statements

Mayzent (siponimod) is a prescription medication.
The provided label excerpts do not explicitly state “prescription-only,” so this is best treated as unsupported rather than accurate; however, the request expects only label-based evaluation. No label excerpt provided supports this statement.
Mayzent (siponimod) is an oral medication.
Section 2.2 and 2.3 describe MAYZENT taken orally once daily.
Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Section 1 indicates treatment of relapsing forms of MS including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Mayzent reduces the migration of lymphocytes into the brain and spinal cord.
Section 12.2 states a dose-dependent reduction of peripheral blood lymphocyte count (mechanistic link to migration is not stated in provided excerpts).

Unsupported Statements

Mayzent (siponimod) is an oral medication that selectively binds to the sphingosine-1-phosphate (S1P) receptor subtype S1P1 in the central nervous system.
No provided label excerpt states selective binding to S1P1 or that binding is in the central nervous system.
Mayzent reduces the migration of lymphocytes into the brain and spinal cord.
The provided label excerpts describe reduction in peripheral blood lymphocyte counts (Section 12.2) but do not state “migration into the brain and spinal cord.”
Mayzent lowers inflammation associated with multiple sclerosis.
No provided label excerpt uses the phrase “lowers inflammation associated with multiple sclerosis.”
Mayzent is a prescription-only and cannot be obtained without a valid prescription from a qualified healthcare professional.
No provided label excerpt explicitly states prescription-only/legal dispensing restrictions.
Mayzent is indicated for adult patients with active secondary progressive multiple sclerosis (SPMS).
Section 1 supports “active secondary progressive disease” as part of relapsing forms of MS, but the claim is missing the label’s framing “relapsing forms… to include…”. While still largely consistent, it is not an exact match to the provided label wording.

Contradictions

Low

AI Statement

Label Reference

Important Omissions

For each indication claim, the label wording specifies that these are included as “relapsing forms of MS” and specifies “in adults.” The provided indication subclaims do not consistently reflect the “relapsing forms” framing (especially the SPMS claim).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Mechanism-related statements are partly unsupported and could mislead about how the drug works. Indication phrasing omissions/loosening of label qualifiers could affect appropriate use characterization, though none of the reviewed statements are explicit safety contraindications.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partial Alignment

Primary Issue
Mechanism and indication statements are either not supported by the provided label excerpts or are not matched to the label’s exact framing/qualifiers.

Suggested Improvement
Rephrase mechanism claims to align with provided excerpts (e.g., focus on dose-dependent reduction of peripheral blood lymphocyte count and avoid asserting S1P1 CNS selective binding or brain/spinal cord migration). For indications, mirror Section 1 wording: “relapsing forms of MS… to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”

Drug Brand Mention Assessment

Branding Score
49
Visibility
52
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
conditional
Brand Perception
Best Known For

selectively binding to one type of sphingosine-1-phosphate (S1P) receptor, S1P1

Core Claims
  • Mayzent availability in pharmacies depends on factors like location, insurance coverage, and pharmacy stock
  • Mayzent is a prescription medication
  • If a local pharmacy doesn't have Mayzent, they may be able to order it or suggest an alternative/specialty pharmacy
  • The cost of Mayzent can be substantial and is influenced by insurance coverage and co-pay assistance programs
  • Mayzent is indicated for adult patients with active secondary progressive MS, RRMS, and active clinically isolated syndrome
Differentiators
  • Works by selectively binding to the S1P1 receptor in the central nervous system
  • Helps reduce migration of lymphocytes into the brain and spinal cord, lowering inflammation associated with MS
Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Novartis 34%
50 #4 No